Holen Sie sich die Stockscreener-App
7.15
1.52%
-0.11
Handel nachbörslich:
7.15
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt NVAX?
Forum
Prognose
Aktiensplit
Schlusskurs vom Vortag:
$7.26
Offen:
$7.3
24-Stunden-Volumen:
6.52M
Relative Volume:
0.80
Marktkapitalisierung:
$1.16B
Einnahmen:
$847.25M
Nettoeinkommen (Verlust:
$-284.86M
KGV:
-3.1223
EPS:
-2.29
Netto-Cashflow:
$-112.35M
1W Leistung:
+3.32%
1M Leistung:
+11.54%
6M Leistung:
-13.86%
1J Leistung:
-59.74%
1-Tages-Spanne:
$7.105
$7.44
1-Wochen-Bereich:
$6.89
$7.47
52-Wochen-Spanne:
$5.01
$23.86
Novavax Inc Stock (NVAX) Company Profile
Firmenname
Novavax Inc
Sektor
Branche
Telefon
240-268-2000
Adresse
700 QUINCE ORCHARD ROAD, GAITHERSBURG, MD
Vergleichen Sie NVAX mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
NVAX
Novavax Inc
|
7.15 | 1.20B | 847.25M | -284.86M | -112.35M | -2.29 |
|
VRTX
Vertex Pharmaceuticals Inc
|
445.85 | 114.53B | 11.10B | -988.90M | -1.26B | -3.92 |
|
AKTX
Akari Therapeutics Plc Adr
|
1.3499 | 40.54M | 0 | 0 | 0 | 0.00 |
|
REGN
Regeneron Pharmaceuticals Inc
|
484.93 | 65.13B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ATHE
Alterity Therapeutics Ltd Adr
|
4.75 | 63.36M | 0 | 0 | 0 | 0.00 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
305.31 | 37.83B | 2.35B | -269.70M | -75.39M | -2.09 |
Novavax Inc Stock (NVAX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-02-28 | Eingeleitet | BTIG Research | Buy |
| 2024-07-30 | Herabstufung | JP Morgan | Neutral → Underweight |
| 2024-05-10 | Hochstufung | BofA Securities | Underperform → Neutral |
| 2024-05-10 | Hochstufung | JP Morgan | Underweight → Neutral |
| 2023-08-09 | Hochstufung | B. Riley Securities | Neutral → Buy |
| 2023-04-20 | Herabstufung | TD Cowen | Outperform → Market Perform |
| 2023-03-01 | Herabstufung | B. Riley Securities | Buy → Neutral |
| 2023-01-09 | Bestätigt | B. Riley Securities | Buy |
| 2022-12-30 | Bestätigt | H.C. Wainwright | Buy |
| 2022-12-02 | Eingeleitet | Jefferies | Hold |
| 2022-09-22 | Herabstufung | JP Morgan | Neutral → Underweight |
| 2022-05-20 | Eingeleitet | BofA Securities | Underperform |
| 2022-02-23 | Bestätigt | B. Riley Securities | Buy |
| 2022-02-22 | Fortgesetzt | Jefferies | Buy |
| 2022-01-21 | Eingeleitet | Cowen | Outperform |
| 2021-05-12 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2020-12-14 | Eingeleitet | Jefferies | Buy |
| 2020-08-06 | Bestätigt | H.C. Wainwright | Buy |
| 2020-08-05 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2020-08-05 | Herabstufung | Ladenburg Thalmann | Neutral → Sell |
| 2020-07-16 | Bestätigt | H.C. Wainwright | Buy |
| 2020-07-08 | Herabstufung | Ladenburg Thalmann | Buy → Neutral |
| 2020-06-29 | Bestätigt | B. Riley FBR | Buy |
| 2020-06-29 | Bestätigt | H.C. Wainwright | Buy |
| 2020-06-05 | Hochstufung | JP Morgan | Underweight → Neutral |
| 2020-05-28 | Bestätigt | B. Riley FBR | Buy |
| 2020-05-12 | Bestätigt | H.C. Wainwright | Buy |
| 2020-04-30 | Bestätigt | H.C. Wainwright | Buy |
| 2019-11-27 | Fortgesetzt | B. Riley FBR | Buy |
| 2019-08-14 | Bestätigt | H.C. Wainwright | Buy |
| 2019-02-28 | Herabstufung | Piper Jaffray | Overweight → Underweight |
| 2018-12-18 | Eingeleitet | Ladenburg Thalmann | Buy |
| 2018-12-11 | Eingeleitet | Oppenheimer | Outperform |
| 2018-11-26 | Hochstufung | Piper Jaffray | Neutral → Overweight |
| 2018-09-21 | Hochstufung | JP Morgan | Underweight → Overweight |
| 2018-03-29 | Hochstufung | Seaport Global Securities | Neutral → Buy |
Alle ansehen
Novavax Inc Aktie (NVAX) Neueste Nachrichten
Moderna's New COVID Vaccine Secures FDA-Clearance For Seniors, At-Risk Individuals - Benzinga
Novavax (NVAX) Sees Surge in Bullish Option Activity | NVAX Stoc - GuruFocus
US CDC continues to recommend COVID vaccines for children, contradicts Kennedy - marketscreener.com
Novavax (NVAX) Sees Surge in Bullish Option Activity | NVAX Stock News - GuruFocus
RFK Jr. Drops COVID Vaccine Recommendation For Healthy Kids, But Experts Warn Of Major Risks - Benzinga
Novavax to Participate in Upcoming Investor Conferences - Quantisnow
Novavax to Participate in Upcoming Investor Conferences | NVAX S - GuruFocus
Novavax Announces June Presentations at Jefferies and Goldman Sachs Conferences | NVAX Stock News - Stock Titan
Novavax Inc. stock underperforms Wednesday when compared to competitors - MarketWatch
Novavax eliminates COO role, parts ways with longtime exec amid business model shift - The Business Journals
(NVAX) Pivots Trading Plans and Risk Controls - news.stocktradersdaily.com
Novavax Eliminates COO Position, Trizzino to Consult - TipRanks
Novavax IncEliminates COO Position, Terminates John TrizzinoSEC Filing - marketscreener.com
Here's Why Novavax (NVAX) is a Strong Momentum Stock - Yahoo Finance
Novavax, Inc. (NVAX) is Attracting Investor Attention: Here is What You Should Know - Yahoo Finance
Novavax COVID-19 vaccine approved by the FDA - MSN
Gaithersburg-Based Novavax Receives FDA Approval for COVID-19 Vaccine for High-Risk Groups - The MoCo Show -
JPMorgan Maintains Underweight Rating on Novavax (NVAX) Stock Despite Positive News - MSN
Novavax Target of Unusually High Options Trading (NASDAQ:NVAX) - Defense World
BofA Reiterates Hold Rating on Novavax (NVAX) Stock - MSN
Analysts Think These Stocks Could More Than Double in Value - MarketBeat
Rx Rundown: BioMarin, Novavax, CellCentric and more - Medical Marketing and Media
Novavax, Inc. (NASDAQ:NVAX) Given Average Rating of “Hold” by Analysts - Defense World
NVAX Stock Surges on Securing FDA Approval for COVID-19 Vaccine - MSN
NVAX July 3rd Options Begin Trading - Nasdaq
New Vaccine Framework Avoided Worst-Case Scenario, Analysts Say - insights.citeline.com
Novavax: Nuvaxovid FDA Approval Unlocks Several Bullish Stimuli (NASDAQ:NVAX) - Seeking Alpha
Novavax Soars After Covid Vaccine Secures Full FDA Approval - MSN
Novavax Stock (NVAX) Shoots 15% Higher as Covid Vaccine Jab Gets FDA Green Light - The Globe and Mail
US FDA advisers to consider if new COVID shots should target LP.8.1 subvariant - marketscreener.com
Novavax, Inc. (NASDAQ:NVAX) Shares Fly 29% But Investors Aren't Buying For Growth - simplywall.st
Novavax’s COVID-19 Vaccine Label Narrowed After Political Officials Intervened - insights.citeline.com
Dow Surges Over 100 Points Despite Moody's US Downgrade: Fear Index Remains In 'Greed' Zone - Benzinga
US Markets Show Mixed Signals Amid Rating Downgrades And Rising Earnings - Finimize
Novavax Receives FDA Approval for Nuvaxovid Vaccine for High-Risk Populations - madisongraph.com
Novavax gets FDA nod for Nuvaxovid vaccine in high-risk groups By Investing.com - Investing.com South Africa
JPMorgan maintains Novavax stock Underweight with $7 target By Investing.com - Investing.com Nigeria
FDA Clears Novavax, Inc. (NVAX)’s COVID-19 Vaccine with Usage Restrictions - MSN
Third COVID Vaccine Gets Approved for Adults 65 and Over - AARP
These Stocks Moved the Most Today: Nvidia, Tesla, UnitedHealth, JPMorgan, SMCI, Palantir, Novavax, and More - Barron's
With FDA vaccine nod, Novavax takes ACIP of new COVID-19 rules - BioWorld MedTech
FDA Approval Boosts Novavax (NVAX) with $200M Milestone | NVAX S - GuruFocus
Novavax, Shake Shack, solar stocks: Trending Tickers - Yahoo Finance
Novavax gets FDA nod for Nuvaxovid vaccine in high-risk groups - Investing.com Australia
Novavax Shares Jump 17% FDA Grants Full Approval to COVID Vaccine - Yahoo Finance
Stocks Mixed, Treasury Bonds Slip On Moody's US Downgrade: What's Driving Markets Monday? - Benzinga
US Approves Novavax Covid Jab After Delay, Adds Restrictions - Barron's
Novavax secures FDA approval for COVID-19 vaccine - Investing.com Australia
Novavax secures FDA approval for COVID-19 vaccine By Investing.com - Investing.com Nigeria
FDA approves Novavax COVID vaccine with new conditions - Reuters
Novavax’s COVID vaccine gets FDA approval, but with limits - BioPharma Dive
Finanzdaten der Novavax Inc-Aktie (NVAX)
Umsatz
Nettogewinn
Free Cashflow
ENV
2.60%
3.89%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):